News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Dangerous & wrong narrative being promulgated by ISPOR – Richard Sullivan
Photo from womenandcancercommission.org
Jul 11, 2023, 18:24

Dangerous & wrong narrative being promulgated by ISPOR – Richard Sullivan

Dangerous & wrong narrative being promulgated by ISPOR “Continued reliance on .. OS benefit as the primary measure of innovation in oncology ….restrict(s) patient access to innovative therapies & leads to higher healthcare costs”.
For details: Click here
Source: Richard Sullivan/Twitter
cancer Headlines healthcare Innovation ISPOR OncoDaily Oncology Richard Sullivan
Special Coverage
Blog
Nov 16, 2024, 21:19
Zahra Ramji: The unique challenges of conducting clinical trials in low and middle-income countries
Blog
Nov 16, 2024, 21:15
Olubukola Ayodele: Honoured to organise the cancer health disparities meeting as the finale event of LGCW
Blog
Nov 16, 2024, 21:08
Mohit Manrao: 4 Takeaways from Milken Institute Future of Health Summit
Insight
Nov 16, 2024, 21:03
Ultrasound-stimulated microbubbles as a radioenhancer in radiation treatment - Technology in Cancer Research and Treatment
Insight
Nov 16, 2024, 20:35
Kate Dibble: Financial Difficulty Over Time in Young Adults With Breast Cancer
Insight
Nov 16, 2024, 20:28
Naveen Pemmaraju: Our new report on DDX for mediastinal mass in patient with B-ALL
Blog
Nov 16, 2024, 20:04
Paul Sargos: ESTRO pre-meeting courses are here
Blog
Nov 16, 2024, 20:00
Katsuaki Maehara: Non-G12C KRAS mutations
Insight
Nov 16, 2024, 19:57
Praful Ravi: Can oligometastatic prostate cancer be cured with "total therapy"?
Blog
Nov 16, 2024, 18:42
Paolo Tarantino: Focusing on HR+/HER2- Breast Cancer
Blog
Nov 16, 2024, 17:57
Emad Shash: Cancer-Associated Thrombosis
Insight
Nov 16, 2024, 17:21
Nirmala Bhoo Pathy: A roundtable discussion on cancer financing at the Royal Society of Medicine